Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs China SXT Pharmaceuticals, Inc. (SXTC)

Apimeds Pharmaceuticals US, Inc. and China SXT Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $4.1M against $2.0M — 2.0× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −255.2%) and the lower return on invested capital (−16.0% vs 0.00%). Across the 10 metrics below, China SXT Pharmaceuticals, Inc. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 3.

Valuation

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S n/m n/m 2.08
P/B 0.04 n/m 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m 2.66 12.22
EV/Sales n/m (5.94) 2.87
Earnings yield (1,394.72%) (3,722.74%) (15.94%)
Free cash flow yield (295.94%) 0.00% 0.00%

Profitability

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Gross margin — 36.69% 53.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (255.16%) (2.45%)
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (100.13%) 0.00% (0.80%)
Return on assets (84.20%) 0.00% (1.67%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (53.98%) 5.22%
EPS growth (last fiscal year) (205.56%) (162.25%) 42.91%
Revenue growth, 5-year CAGR — (24.94%) 7.24%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.03 0.04
Current ratio 0.51 7.94 2.41
Net debt to EBITDA 0.38 3.86 1.01

Dividend

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric APUS SXTC Drug Manufacturers Specialty & Generic median
Market cap 4.12m 2.02m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack